Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors have the potential to promote long-term gene expression. Unfortunately, humoral immunity restricts patient treatment and in addition provides an obstacle to the potential option of vector readministration. In this study, we describe a comprehensive characterization of the neutralizing antibody (NAb) response to AAV type 1 (AAV1) through AAV5 both in vitro and in vivo. These results demonstrated that NAbs generated from one AAV type are unable to neutralize the transduction of other types. We extended this observation by demonstrating that a rationally engineered, muscle-tropic AAV2 mutant containing 5 amino acid substitutions from AAV1 displayed a NAb profile different from those of parental AAV2 and AAV1. Here we found that a single insertion of Thr from AAV1 into AAV2 capsid at residue 265 preserved high muscle transduction, while also changing the immune profile. To better understand the role of Thr insertion at position 265, we replaced all 20 amino acids and evaluated both muscle transduction and the NAb response. Of these variants, 8 mutants induced higher muscle transduction than AAV2. Additionally, three classes of capsid NAb immune profile were defined based on the ability to inhibit transduction from AAV2 or mutants. While no relationship was found between transduction, amino acid properties, and NAb titer or its cross-reactivity, these studies map a critical capsid motif involved in all steps of AAV infectivity. Our results suggest that AAV types can be utilized not only as templates to generate mutants with enhanced transduction efficiency but also as substrates for repeat administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Capsid engineering for capsids with resistance to antibodies can be performed through rational design (82 -88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 3×
“These results suggest that preexisting NAbs in the human population can attenuate vector transduction efficiency and inhibit transgene expression upon systemic application (44).”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Adeno-associated virus (AAV) vectors have been safely and successfully used in phase I clinical trials (39, 40, 54).”
MethodAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
CD40 AND CD154 IN CELL-MEDIATED IMMUNITY
Grewal, I. S., & Flavell, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.111 · Cited by 1,539 · cited 1×
“Activated T cells then regulate B cell proliferation, production of immunoglobulins (Ig), Ig class switching, rescue of B lymphocytes from apoptotic death, germinal center formation, and generation of B lymphocyte memory (25).”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“In vitro NAb assays, including those performed in this study, have demonstrated a lack of cross-reactivity between different types (22, 23, 26).”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 3×
“In vitro NAb assays, including those performed in this study, have demonstrated a lack of cross-reactivity between different types (22, 23, 26).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 6×
“In the general human population, over 95% of individuals have been infected by AAV2, with 50% of them having NAbs (3, 4, 6, 10, 18, 21, 24, 27, 35, 48, 62, 65).”
BackgroundResultInfluentialXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Self-citationMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“Adeno-associated virus (AAV) vectors have been safely and successfully used in phase I clinical trials (39, 40, 54).”
Method
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citationHastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
“Further, single amino acid changes in the capsid proteins result in vectors with less immunogenicity and improved transduction.(86) Limitations to vector packaging size also continue to be explored and may soon result in generation of vectors with room for larger transgene inserts.”
Self-citationPromoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al. (2015) · Nature · doi:10.1038/nature13864 · Cited by 257
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
Ambalathingal, G. R., Francis, R. S., Smyth, M. J., Smith, C., & Khanna, R. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-16 · Cited by 240
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
“This change resulted in a capsid that was not recognized by mAb A20 (antibody that binds AAV2 and AAV3 capsids) (117), leading to enhanced transduction of skeletal muscle (118).”
BackgroundTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
“These approaches have led to identification of novel capsids with increased transduction efficiency [25] altered tropism [26,39,40] and the ability to evade recognition by the immune system [41].”
BackgroundSelf-citationControlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145
Adeno-Associated Virus Vectors as Therapeutic and Investigational Tools in the Cardiovascular System
Zacchigna, S., Zentilin, L., & Giacca, M. (2014) · Circulation Research · doi:10.1161/circresaha.114.302331 · Cited by 141
“A widely investigated approach involves the modification of capsid immunogenic epitopes by either random mutagenesis or rational design, also by including epitopes specifically activating suppressive T regulatory cells.(62,63) Another possibility involves the use of empty capsids as decoys to adsorb antiAAV antibodies…”
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“These activated CD8+T cells destroy pro-inflammatory cytokines such as IFNγ, TNF-α and IL-2 which can i presenting cells (APC), they are presented throughMHC II complex to T then secrete pro-inflammatory cytokines such as IL-2, IL-4 and IL-5 to fu signals such as CD40L also can recruit other immune cells [54].”
BackgroundBK Polyomavirus Genotypes Represent Distinct Serotypes with Distinct Entry Tropism
Pastrana, D. V., Ray, U., Magaldi, T. G., Schowalter, R. M., Çuburu, N., & Buck, C. B. (2013) · Journal of Virology · doi:10.1128/jvi.01189-13 · Cited by 112
“In experiments using adeno-associated virus (AAV), Li and colleagues have likewise shown that small numbers of amino acid changes in the viral capsid protein can simultaneously shift cellular tropism and also promote escape from antibody-mediated neutralization in experimentally vaccinated animals (10).”
MethodSmall But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 112
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101
“Since single residue mutations can result in dramatic effects on virus phenotypes (25, 26), it is important to understand how host cell molecules and antibodies interact with virus capsid.”
BackgroundSelf-citationAslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
“This further corroborates our recent observation of the critical role played by specific amino acid type in modulating the biological activity of AAV vectors [12,42].”
ResultSelf-citationLiu, Q., Huang, W., Zhang, H., Wang, Y., Zhao, J., Song, A., Xie, H., Zhao, C., Gao, D., & Wang, Y. (2014) · Gene Therapy · doi:10.1038/gt.2014.47 · Cited by 93
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Self-citationHumoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
“Through contact with wild-type AAV, humans develop antibodies against the different serotypes in their first years of life.(15,16) Depending on the study, seroprevalence for AAV8 ranges from 15% to 30% of the population (AAV2: 30%– 60%)(16,17) to 82% in Asian adult humans (AAV2: 97%).”
BackgroundMapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier
Albright, B. H., Storey, C. M., Murlidharan, G., Castellanos Rivera, R. M., Berry, G. E., Madigan, V. J., & Asokan, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.017 · Cited by 82
“This region has previously been implicated as being important in determining the tropism and antigenicity of AAV1.(24,25) These residues are exposed on the surface of the capsid at the base of the protrusions at the 3-fold axis of symmetry (Figures S2D and S2F) and are also localized at the depression at the 2-fold sy…”
BackgroundSelf-citationMarsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje-McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 72
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection
Shen, C.-L., Wu, B.-S., Lien, T.-J., Yang, A., & Yang, C. (2021) · Viruses · doi:10.3390/v13030487 · Cited by 75
“virus can hide away from neutralization with a mutation in viral antibody receptors [22,23].”
BackgroundEvolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 72
“For example, a monoclonal antibody A20 was identified to bind AAV2 through residue 265 of VP1 protein.”
BackgroundGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
“In particular, the resolution of the structure of AAV2 complexed with a monoclonal antibody (69) enabled rational mutation of the AAV2 sequence to avoid neutralization from this specific clone (70).”
BackgroundLevings, R. W., Broome, T. A., Smith, A. D., Rice, B. L., Gibbs, E. P., Myara, D. A., Hyddmark, E. V., Nasri, E., Zarezadeh, A., Levings, P. P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.142 · Cited by 71
Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
“This required engineering efforts that use rational design to strategically evade or dampen the innate immune response [17].”
BackgroundWoodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
“5 capsid to be solely responsible (42).”
Self-citationA versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Pandya, J., Ortiz, L., Ling, C., Rivers, A. E., & Aslanidi, G. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.74 · Cited by 55
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Simon Sola, M., Masat, E., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
“were noted in IgG or NAb titers in all age groups, a result in line with previously published surveys [33, 40, 54, 55].”
ResultRecent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 60
Targeted approaches to induce immune tolerance for Pompe disease therapy
Doerfler, P. A., Nayak, S., Corti, M., Morel, L., Herzog, R. W., & Byrne, B. J. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.53 · Cited by 51
Wang, M., Sun, J., Crosby, A., Woodard, K., Hirsch, M. L., Samulski, R. J., & Li, C. (2017) · Gene Therapy · doi:10.1038/gt.2016.75 · Cited by 51
“At the level of the AAV capsid, much attention has been focused on employing natural serotypes that display differential tropisms, rationally designed capsids, or capsids selected or screened from a mutant capsid library(9-11).”
BackgroundSelf-citationStanford, S., Pink, R., Creagh, D., Clark, A., Lowe, G., Curry, N., Pasi, J., Perry, D., Fong, S., Hayes, G., et al. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12177 · Cited by 49
Li, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Self-citationLevings, R. W., Smith, A. D., Broome, T. A., Rice, B. L., Gibbs, E. P., Myara, D. A., Hyddmark, E. V., Nasri, E., Zarezadeh, A., Levings, P. P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.143 · Cited by 54
Prediction of adeno-associated virus neutralizing antibody activity for clinical application
Wang, M., Crosby, A., Hastie, E., Samulski, J. J., McPhee, S., Joshua, G., Samulski, R. J., & Li, C. (2015) · Gene Therapy · doi:10.1038/gt.2015.69 · Cited by 45
Self-citationGoodrich, L. R., Grieger, J. C., Phillips, J. N., Khan, N., Gray, S. J., McIlwraith, C. W., & Samulski, R. J. (2015) · Gene Therapy · doi:10.1038/gt.2015.21 · Cited by 50
Self-citationGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“Other alternatives can also be explored, such as modulating the dose or using less prevalent or less immunogenic(27,75) AAV serotypes or even capsid-modified rAAV.(76) Indeed, the transduction efficiency of dendritic cells (DCs) depends on AAV serotype and/or genome conformation (ss versus self-complementary) and migh…”
BackgroundGene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation
Levings, R. W., Palmer, G. D., Levings, P. P., Dacanay, E. A., Evans, C. H., & Ghivizzani, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901317 · Cited by 52
“The generation of designer AAV capsids with enhanced properties for specific applications using rational design (Li et al., 2012; Wang et al., 2019), directed evolution, (Marsic et al.”
BackgroundMitchell, A. M., Li, C., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.03443-12 · Cited by 41
“vectors has been previously described (44).”
Self-citationPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
Recombinant Adeno-Associated Virus Utilizes Cell-Specific Infectious Entry Mechanisms
Weinberg, M. S., Nicolson, S., Bhatt, A. P., McLendon, M., Li, C., & Samulski, R. J. (2014) · Journal of Virology · doi:10.1128/jvi.01971-14 · Cited by 39
Self-citationAn Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“The ability to confer altered antigenicity has since been narrowed down to a single amino acid at position 265 and appears to mediate decreased recognition by antisera when administered in mice (Li et al., 2012).”
BackgroundSelf-citationAdenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy
Young, D., Fong, D. M., Lawlor, P. A., Wu, A. J., Mouravlev, A., McRae, M., Glass, M., Dragunow, M., & During, M. J. (2014) · Gene Therapy · doi:10.1038/gt.2014.82 · Cited by 45
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 38
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Wu, F., Luo, S., Zhang, Y., Ou, Y., Wang, H., Guo, Z., He, C., Bai, S., He, P., Jiang, M., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.004 · Cited by 36
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Stutz, H. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115089 · Cited by 38
“More-over, mutations in VPs may influence patient immune responses and the efficiency of transduction [347].”
BackgroundSelot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“Techniques such as site-specific mutagenesis strategies are helpful in the stepwise introduction of point mutations within the target epitopes to generate vectors with immune evasion properties [30, 37-40].”
Atomic structure of a rationally engineered gene delivery vector, AAV2. 5
Burg, M., Rosebrough, C., Drouin, L. M., Bennett, A., Mietzsch, M., Chipman, P., McKenna, R., Sousa, D., Potter, M., Byrne, B., et al. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.05.004 · Cited by 30
Self-citationDavey, M. G., Riley, J. S., Andrews, A., Tyminski, A., Limberis, M., Pogoriler, J. E., Partridge, E., Olive, A., Hedrick, H. L., Flake, A. W., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171132 · Cited by 30
Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity
Pei, X., Shao, W., Xing, A., Askew, C., Chen, X., Cui, C., Abajas, Y. L., Gerber, D. A., Merricks, E. P., Nichols, T. C., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.003 · Cited by 35
“Our previous studies have demonstrated that modification of the residue 265 demonstrated a decreased ability to bind to A20 and resisted A20 neutralizing activity.(23) In support of this finding, this study shows most selected mutants demonstrated swapping of the domain covering residue 265 from other serotypes while…”
BackgroundResultSelf-citationIdentification of adeno-associated virus capsid proteins using ZipChip CE/MS
Zhang, Y., Wang, Y., Sosic, Z., Zang, L., Bergelson, S., & Zhang, W. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.06.006 · Cited by 27
Cabanes‐Creus, M., Navarro, R. G., Liao, S. H. Y., Baltazar, G., Drouyer, M., Zhu, E., Scott, S., Luong, C., Wilson, L. O. W., Alexander, I. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.010 · Cited by 29
“5.(24) Furthermore, saturation studies at this particular position showed that the increased murine muscle tropism was correlated with the amino acid insertion, resulting in a structural change, and it was not linked to any particular amino acid, which is in agreement with our saturation data (Figure 4).”
ResultInfluentialChai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 27
Self-citationOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 29
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
Marino, M., & Holt, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.870799 · Cited by 22
“5 capsid recognized by the monoclonal antibody A20 reduces levels of vector neutralization (127); while the chimera AAV-DJ shows the ability to evade neutralizing antibodies generated by exposure to other serotypes (128).”
BackgroundSystemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection
Lipinski, D. M., Reid, C. A., Boye, S. L., Peterson, J. J., Qi, X., Boye, S. L., Boulton, M. E., & Hauswirth, W. W. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.097 · Cited by 25
AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement
Pei, X., He, T., Hall, N. E., Gerber, D., Samulski, R. J., & Li, C. (2018) · Virology · doi:10.1016/j.virol.2018.02.007 · Cited by 23
Self-citationProgress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors
Liu, J., Koay, T. W., Maiakovska, O., Zayas, M., & Grimm, D. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.057 · Cited by 23
Krotova, K. Y., & Aslanidi, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.074 · Cited by 18
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
Self-citationSun, J., Hua, B., Chen, X., Samulski, R. J., & Li, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.016 · Cited by 16
“For example, AAV vectors have been coated with polymers such as polyethylene glycol, directionally evolved in vitro and in vivo in the presence of neutralizing antibodies to obtain novel AAV capsid variants, or rationally mutated to eliminate antibody recognition sites.(14) Other AAV serotypes that exhibit little to n…”
BackgroundSelf-citationGilkes, J. A., Judkins, B. L., Herrera, B. N., Mandel, R. J., Boye, S. L., Boye, S. L., Srivastava, A., & Heldermon, C. D. (2020) · Gene Therapy · doi:10.1038/s41434-020-00206-w · Cited by 15
Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer
Pandya, M., Britt, K., Hoffman, B. E., Ling, C., & Aslanidi, G. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000093 · Cited by 13
Haar, J., Blazevic, D., Strobel, B., Kreuz, S., & Michelfelder, S. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.008 · Cited by 11
Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies
Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y. (2014) · BioMed Research International · doi:10.1155/2014/818107 · Cited by 12
“At this point, specific antibodies against the particles of AAVs are produced and then eliminated by neutrophils and DCs [59].”
BackgroundInfluentialPromise of adeno-associated virus as a gene therapy vector for cardiovascular diseases
Bera, A., & Sen, D. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9622-7 · Cited by 13
Hoad, M., Roby, J. A., & Forwood, J. K. (2021) · FEBS Letters · doi:10.1002/1873-3468.14209 · Cited by 10
Rationally engineered novel AAV capsids for intra-articular gene delivery
Li, W., Feng, S. L., Herrschaft, L., Samulski, R. J., & Li, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101211 · Cited by 12
Self-citationMeyer, N., Davulcu, O., Xie, Q., Silveria, M., Zane, G. M., Large, E. E., & Chapman, M. S. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3513 · Cited by 10
“Strategies for developing immune-escape variants are currently being explored (Li et al., 2012; McCraw et al., 2012; Tseng and Agbandje-McKenna, 2014; Buning et al., 2015; Majowicz et al., 2017; Paulk et al., 2018).”
BackgroundNonclinical strategies and considerations to enable the redosing of gene therapies
Moffit, J. S., Alatsis, K. R., Blanset, D. L., Buss, N. A. P. S., & Rana, P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101520 · Cited by 9
“40 However, challenges remain, as modifications to the capsid surface may not fully mask the underlying antigenic epitopes that are conserved across serotypes.”
A single amino acid variant in the variable region I of AAV capsid confers liver detargeting
Xing, R., Xu, M., Reil, D., Destefano, A., Cui, M., Liu, N., Liang, J., Xu, G., Luo, L., Xu, M., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013533 · Cited by 8
“5 [9].”
Host and viral RNA dysregulation during BK polyomavirus infection in kidney transplant recipients
Yaghobi, R., Afshari, A., & Roozbeh, J. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1769 · Cited by 7
“Regarding humoral immunity, the presence of the viral-specific antibodies is not adequate for inducing complete protection against activation and BKPyV-related diseases due to mutations in the viral receptors (Li et al., 2012; O'Donnell et al., 2012).”
BackgroundGene therapy for hemophilia: advancing beyond the first clinical success
Monahan, P. E., & Gui, T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c1a1 · Cited by 9
Self-citationDaniel, H. D. J., Kumar, S., Kannangai, R., Farzana, J., Joel, J. N., Abraham, A., Lakshmi, K. M., Agbandje‐McKenna, M., Coleman, K. E., Srivastava, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27859 · Cited by 6
“Novel vector technologies have also been developed to produce mutant capsids that can escape the high antibody prevalence of wild‐ type capsids.(29) AUTHOR CONTRIBUTIONS All authors certify that they have participated in the concept, design, analysis, writing, or revision of the manuscript.”
BackgroundSelf-citationNeurons under genetic control: What are the next steps towards the treatment of movement disorders?
Tsanov, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.012 · Cited by 6
Yadav, D., & Malviya, R. (2023) · Current Gene Therapy · doi:10.2174/0115665232264527231013072728 · Cited by 4
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Self-citationPak, A., Wear, D., Tahmasian, N., Min, J. Y., Premraj, D. K., Gibbs, R., Spencer, K. A., Fang, S., Zerbes, T., Krishnan, M. R., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1768545 · Cited by 3
“…capsid through site-directed mutagenesis, for instance, the swapping of a surface-exposed tyrosine or threonine with less polar phenylalanine or valine residues, respectively (Markusic et al., 2010; Gilkes et al., 2021), or the systematic replacement of one or a more amino acids (Li et al., 2012).”
Recent developments in gene therapy research in India
Selot, R., & Ghosh, A. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00423-0 · Cited by 7
Adeno‐associated virus‐9 reverses delayed gastric emptying of solids in diabetic mice
Li, X., Ji, S., Cipriani, G., Hillestad, M. L., Eisenman, S. T., Barry, M. A., Nath, K. A., Linden, D. R., Wright, A. M., AlAsfoor, S., et al. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14669 · Cited by 2
“50,51 It has been reported that CD8 + regulatory T cells are critical in prevention of autoimmune-mediated diabetes in STZ mice.”
BackgroundJones, S., & Gill, D. R. (2014) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0005749.pub2 · Cited by 1
Gene therapy to reduce joint inflammation in horses
Colahan, P. T., Watson, R., & Ghivizzani, S. C. (2016) · Wiley eBooks · doi:10.1002/9781118832431.ch13 · Cited by 1
Mitchell, A. M. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f5kg-n202
Gene Transfer in Spinal Muscular Atrophy
Foust, K. D., & Kaspar, B. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00019-7
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58 · Cited by 1
Fong, D. M., Wu, A. J., & Young, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00002-8 · Cited by 1
AAV-Nrf2 Mediated Rescue of Oxidative Stress in Mouse Models
Liang, K. J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tmc2-r921
DETERMINANTS OF AAV TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
Albright, B. H. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vnpr-wx33
APPLICATION OF RADIOISOTOPES AND IONIZING RADIATION FOR INSECT CONTROL.
Kloft, W., Suess, A., & Haisch, A. (1971) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Metadata
- Authors
- Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Department of Biochemistry and Molecular Biology, Center for Structural Biology, The McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2012-08
- Volume
- 86
- Issue
- 15
- Pages
- 7752-7759
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3421647
- OpenAlex
- W2107586018
- Cited by
- 96
- References
- 69
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 10 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 10 · 2014: 10 · 2013: 9
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5u54ar056953-05)
- National Heart, Lung, and Blood Institute (P01HL059412, R01HL089221)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI072176, R01AI080726, AI072176)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084033, DK084033)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54-AR056953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, AAV capsid, amino acid substitutions, neutralizing antibodies, humoral immunity, AAV1, AAV2, AAV5, capsid engineering, cross-reactivity, gene therapy vectors
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Capsid, Cell Line, Chlorocebus aethiops, Female, Humans, Male, Mice, Inbred BALB C, Transduction, Genetic, Muscle, Skeletal, COS Cells, Amino Acid Substitution, Mice, Immunity, Humoral, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.